Stuart Silverman, MD
Rheumatology · Beverly Hills, CANPI 1679670822
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $197,035 of the $301,226 with a category attached, or 65.4%. 51 manufacturers reported payments, led by Amgen at 34.4% of the total. Reporting peaked in 2019 at $106,599 and has fallen 81.3% since, to $19,918 in 2025. Among rheumatology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,138 payments — averaging $264.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$104K
- Eli Lilly$74K
- Radius Health, Inc.$65K
- Tonix Medicines, Inc.$11K
- GSK$10K
- Sandoz$10K
- plus $28K from 45 others
Across 44 payments — averaging $14,775 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$234K
- Amgen$212K
- Roche Diagnostics Corporation$110K
- Regeneron$55K
- Radius Health, Inc.$39K
What the payments were for
- Consulting fees$197,03565%
- Speaking & faculty fees$50,41517%
- Travel & lodging$24,6438%
- Food & beverage$23,5568%
- Education$5,5772%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$301,226 in reported general payments places this provider in the 95th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 73 | $334,492 |
| TymlosAbaloparatide | 78 | $212,332 |
| Teriparatide | 49 | $172,150 |
| ProliaDenosumab | 93 | $157,125 |
| Enbrel SureclickEtanercept | 14 | $105,843 |
| Xeljanz XrTofacitinib Citrate | 13 | $70,372 |
| Orencia ClickjectAbatacept | 11 | $65,357 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 25 | $60,271 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 21 | $53,420 |
| OzempicSemaglutide | 22 | $29,197 |
| MounjaroTirzepatide | 18 | $18,533 |
| MyrbetriqMirabegron | 21 | $12,176 |
| Colchicine | 66 | $5,871 |
| HorizantGabapentin Enacarbil | 11 | $5,017 |
| Nimodipine | 32 | $4,669 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo, Mounjaro | $729 | $353,02591 claims |
| AmgenProlia, Evenity (2 Syringes) | $103,581 | $217,396118 claims |
| Radius Health, Inc.Tymlos | $65,368 | $212,33278 claims |
| Alvogen IncTeriparatide | $378 | $172,15049 claims |
| Novo NordiskOzempic | $28 | $29,19722 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $19 | $5,01711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 rheumatology providers in California.
Other rheumatology in Beverly Hills
- Daniel WallaceBeverly Hills$309K
- Christine LeeBeverly Hills$304K
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.